News About: Pharm. Industry


It is urgent to manage CSOs working as front desk for illegal rebates between pharmas and doctors

The Seoul Western District Prosecutor’s Office announced an investigation result that a nutrient agent company was involved with CSOs to provide illegal rebates, which had created special attention to CSOs. In the ci...

Janssen, “We’ll carry out extensive & global Phase II clinical trial of Hanmi Pharm’s obesity and diabetes biologic”

Hanmi Pharm’s new obesity & diabetes biologic being developed by Janssen  HM12525A(Janssen Code Name: JNJ-64565111) will additionally take an extensive global Phase II clinical trial. This Phase II clinical trial wil...

AstraZeneca to discover new drugs through ‘open innovation’

Multinational pharmaceutical company AstraZeneca seems to expand its pipelines by actively taking open innovation activities to develop new drugs. AstraZeneca Korea held the ‘ASK AZK 2018’ with medical journalists on...

Valsartan case containing carcinogenic substances will bring negative impacts

Started with the Valsartan case, conflicts between doctors and pharmacists have led to discussions about rebates for pharmaceutical companies. Doctors have opposed to the international proprietary names – this has be...

Pharmaceutical companies still strong in quasi drug market for 4 years

For the past 4 years, a pharmaceutical company made the top sales in the quasi drug field, and showed consecutive increases in the amount manufactured. On the 13th, Yakup Shinmoon(www.yakup.com) summarized and analyz...

Pharma distribution industry getting close to critical point in drug return

The amount of returned products is reaching the critical point in storages pharmaceutical distribution companies own. These distribution companies are expanding their storages specially for returned products, and the ...

KPA asks KMA to stop blaming on pharmacists over Valsartan incident

As the antihypertensive drug containing Chinse Valsartan ingredients with carcinogenic substances has become a huge issue, it has led to a conflict over capability between doctors and pharmacists unintentionally.  Th...

Korea finds increase in share of clinical trials despite decrease in the world

Despite the trend where the number of trials is decreasing around the world, Korean pharmaceutical companies have reportedly conducted more clinical trials.  The Korea National Enterprise for Clinical Trials(KoNECT) ...

Health insurance benefits on 125 products containing Huahai’s Valsartan temporarily suspended

The health insurance benefits for 125 antihypertensive products which use Chinse ‘Valsartan’ have been suspended. The Ministry of Health and Welfare(MOHW) Pharmaceutical Benefits Division informed the ‘Notification A...

Most companies used Chinese Valsartan ingredients were small and medium-sized

As it was indicated that the active pharmaceutical ingredient ‘Valsartan’ manufactured by Zhejiang Huahai will likely to be used, sales suspension of 91 out of 219 antihypertensive products has been cleared off. The r...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.